<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03354663</url>
  </required_header>
  <id_info>
    <org_study_id>SJM-CIP-10216</org_study_id>
    <nct_id>NCT03354663</nct_id>
  </id_info>
  <brief_title>TactiSense IDE Trial of TactiCath SE for Paroxysmal Atrial Fibrillation</brief_title>
  <acronym>TactiSense</acronym>
  <official_title>Multi-Center Acute Safety Trial of TactiCath™ Contact Force Ablation Catheter, Sensor Enabled™ (TactiCath SE) for the Treatment of Drug Refractory Recurrent Symptomatic Paroxysmal Atrial Fibrillation</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Abbott Medical Devices</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Abbott Medical Devices</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>Yes</is_fda_regulated_device>
    <is_unapproved_device>Yes</is_unapproved_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This clinical investigation is intended to demonstrate the acute safety and effectiveness of
      ablation with the TactiCath™ Contact Force Ablation Catheter, Sensor Enabled™ (TactiCath SE)
      for the treatment of drug refractory recurrent symptomatic paroxysmal atrial fibrillation
      (PAF). This clinical investigation will be conducted under an investigational device
      exemption (IDE) and is intended to support market approval of the TactiCath SE ablation
      catheter in the United States. One hundred fifty six (156) subjects will be enrolled at up to
      35 investigational sites in the US, Europe, and Australia. This clinical investigation is
      sponsored by Abbott.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This is a prospective, multi-center, single-arm clinical trial to demonstrate the acute
      safety and effectiveness of the TactiCath SE catheter for the treatment of PAF against a
      performance goal. One hundred fifty six (156) subjects will be enrolled at up to 35
      investigational sites in the US, Europe, and Australia. Only sites that enroll at least one
      subject will be part of the analysis population. No center may contribute more than 20% of
      the total number of enrollments without sponsor pre-approval to exceed this proportion and at
      least 50% of subjects must be from the United States.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">December 11, 2017</start_date>
  <completion_date type="Actual">October 30, 2019</completion_date>
  <primary_completion_date type="Actual">August 2, 2018</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Rate of Serious Adverse Events</measure>
    <time_frame>30 days</time_frame>
    <description>The primary safety endpoint is the rate of device or procedure-related serious adverse events occurring within 7 days of the index procedure. SAEs related solely to arrhythmia recurrence (without coexisting conditions such as thromboembolism, worsening heart failure, etc.) will not be considered primary safety endpoint events. The SAEs that will be included in this endpoint are:
Atrial-esophageal fistula
AV block
Cardiac Perforation/ Tamponade
Death
Diaphragmatic paralysis
Gastroparesis
Hospitalization
Myocardial Infarction
Pericarditis
Pneumothorax
Pulmonary edema
Pulmonary vein stenosis
Stroke
Thromboembolism
Transient ischemic attack
Vascular access complications
Atrial-esophageal fistula, cardiac perforation/tamponade, and pulmonary vein stenosis that occur &gt;7 days post procedure through 30 days will also contribute to the primary endpoint.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Number of Participants With Procedural Success</measure>
    <time_frame>0 days</time_frame>
    <description>The primary effectiveness endpoint is acute procedural success, where acute procedural success is defined as confirmation of entrance block in all pulmonary veins</description>
  </primary_outcome>
  <other_outcome>
    <measure>Average Power Delivered</measure>
    <time_frame>During Procedure</time_frame>
    <description>This outcome is the average power delivered for a case.</description>
  </other_outcome>
  <other_outcome>
    <measure>Index Cases Achieving ≥ 90% Lesions With ≥ 10 Contact Force</measure>
    <time_frame>0 days</time_frame>
    <description>Proportion of index cases achieving ≥ 90% lesions with ≥10g contact force</description>
  </other_outcome>
  <other_outcome>
    <measure>Number of Participants Experiencing Serious Adverse Events Within 30 Days</measure>
    <time_frame>30 days</time_frame>
    <description>Serious adverse events and adverse events related to the procedure and/or ablation catheter through 30 days post index ablation. This excludes the events identified in the primary safety endpoint.</description>
  </other_outcome>
  <other_outcome>
    <measure>Number of Participants Experiencing a Serious Adverse Event Within 1 Year</measure>
    <time_frame>1 year</time_frame>
    <description>Serious adverse events and adverse events related to the procedure and/or ablation catheter through 1 year post index ablation</description>
  </other_outcome>
  <other_outcome>
    <measure>One-year Freedom From AF</measure>
    <time_frame>1 year</time_frame>
    <description>One-year freedom from AF, defined as freedom from symptomatic AF, atrial flutter (AFL), and atrial tachycardia (AT) lasting longer than 30 seconds through 9 months of follow-up after a 3-month blanking period.</description>
  </other_outcome>
  <other_outcome>
    <measure>One-year Drug-free Success From AF</measure>
    <time_frame>1 year</time_frame>
    <description>One-year drug-free success defined as freedom from any AF/AFL/AT lasting at least 30 seconds or any Class I or III AAD after removal from antiarrhythmic drug therapy as assessed from the end of the 3-month blanking period to 12 months following the ablation procedure.</description>
  </other_outcome>
  <other_outcome>
    <measure>Changes in EQ-5D-5L Scores</measure>
    <time_frame>1 year</time_frame>
    <description>Changes in EQ-5D-5L scores from baseline to follow up at 3, 6, and 12 months</description>
  </other_outcome>
  <other_outcome>
    <measure>Changes in AFEQT Scores</measure>
    <time_frame>1 year</time_frame>
    <description>Changes in AFEQT scores from baseline to follow up at 3, 6, and 12 months</description>
  </other_outcome>
  <other_outcome>
    <measure>Health Care Utilization</measure>
    <time_frame>1 year</time_frame>
    <description>Cardiovascular-related health care utilization through 12 months post index ablation</description>
  </other_outcome>
  <other_outcome>
    <measure>Force Time Integral (FTI) and Lesion Index (LSI)</measure>
    <time_frame>0 days</time_frame>
    <description>FTI and LSI will be derived from the available EnSite Precision data. Descriptive statistics will be generated for both variables.</description>
  </other_outcome>
  <other_outcome>
    <measure>Average Catheter Temperature</measure>
    <time_frame>0 days</time_frame>
    <description>This outcome is the average temperature (by lesion) for a case.</description>
  </other_outcome>
  <other_outcome>
    <measure>Number of Participants With Recommended Irrigation Flow Rate Used During Procedure</measure>
    <time_frame>0 days</time_frame>
    <description>This outcome is whether or not the recommended irrigation flow rate was used for a case.</description>
  </other_outcome>
  <other_outcome>
    <measure>Contact Force During Procedure</measure>
    <time_frame>0 days</time_frame>
    <description>This outcome is the average contact force for a case.</description>
  </other_outcome>
  <other_outcome>
    <measure>Total Procedure Time</measure>
    <time_frame>0 days</time_frame>
    <description>This outcome is the total procedure time for a case.</description>
  </other_outcome>
  <other_outcome>
    <measure>Ablation Time - First to Last Ablation</measure>
    <time_frame>0 Days</time_frame>
    <description>This outcome is the total ablation time for a case. This is the time from first to last ablation.</description>
  </other_outcome>
  <other_outcome>
    <measure>Fluoroscopy Time</measure>
    <time_frame>0 days</time_frame>
    <description>This outcome is the total fluoroscopy time for a case.</description>
  </other_outcome>
  <other_outcome>
    <measure>Radiofrequency (RF) Application Time</measure>
    <time_frame>0 days</time_frame>
    <description>This outcome is the total RF application time for a case.</description>
  </other_outcome>
  <other_outcome>
    <measure>Number of Participants Using AutoMark</measure>
    <time_frame>0 days</time_frame>
    <description>This outcome is the number of cases using AutoMark.</description>
  </other_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">156</enrollment>
  <condition>Paroxysmal Atrial Fibrillation</condition>
  <arm_group>
    <arm_group_label>TactiCath SE</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Catheter ablation with the TactiCath SE ablation catheter to achieve pulmonary vein isolation.</description>
  </arm_group>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>TactiCath SE</intervention_name>
    <description>Ablation to achieve pulmonary vein isolation.</description>
    <arm_group_label>TactiCath SE</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Plans to undergo a catheter ablation procedure due to symptomatic PAF that is
             refractory or intolerant to at least one Class I or III antiarrhythmic drug

          -  Physician's note indicating recurrent self-terminating AF

          -  One electrocardiographically documented AF episode within 6 months prior to the index
             ablation procedure

          -  At least 18 years of age

          -  Able and willing to comply with all trial requirements

          -  Informed of the nature of the trial, agreed to its provisions and has provided written
             informed consent as approved by the Institutional Review Board/Ethics Committee
             (IRB/EC) of the respective clinical trial site.

        Exclusion Criteria:

          -  Persistent or long-standing persistent atrial fibrillation (AF)

          -  Four or more cardioversions in the past 12 months

          -  Active systemic infection

          -  Known presence of cardiac thrombus

          -  Implanted with implantable cardiac defibrillator (ICD)

          -  Arrhythmia due to reversible causes including thyroid disorders, acute alcohol
             intoxication, and other major surgical procedures in the preceding 3 months

          -  Myocardial infarction (MI), acute coronary syndrome, percutaneous coronary
             intervention (PCI), or valve or coronary bypass grafting surgery within preceding 3
             months

          -  Left atrial diameter &gt; 5.0 cm

          -  Left ventricular ejection fraction &lt; 35%

          -  New York Heart Association (NYHA) class III or IV

          -  Previous left atrial surgical or catheter ablation procedure

          -  Left atrial surgical procedure or incision with resulting scar

          -  Previous tricuspid or mitral valve replacement or repair

          -  Heart disease in which corrective surgery is anticipated within 6 months

          -  Bleeding diathesis or suspected procoagulant state

          -  Contraindication to long term antithromboembolic therapy

          -  Presence of any condition that precludes appropriate vascular access

          -  Renal failure requiring dialysis

          -  Known sensitivity to contrast media (if needed during the procedure) that cannot be
             controlled with pre-medication

          -  Severe pulmonary disease (e.g., restrictive pulmonary disease, constrictive or chronic
             obstructive pulmonary disease) or any other disease or malfunction of the lungs or
             respiratory system that produces severe chronic symptoms

          -  Pregnant or nursing

          -  Presence of other anatomic or comorbid conditions that, in the investigator's opinion,
             could limit the patient's ability to participate in the clinical trial or to comply
             with follow up requirements, or impact the scientific soundness of the clinical trial
             results

          -  Patient is currently participating in another clinical trial or has participated in a
             clinical trial within 30 days prior to screening that may interfere with this clinical
             trial

          -  Patient is unlikely to survive the protocol follow up period of 12 months

          -  Body mass index &gt; 40 kg/m2

          -  Vulnerable subject
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Kristin Ruffner, PhD MBA</last_name>
    <role>Study Director</role>
    <affiliation>Abbott</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Arkansas Heart Hospital</name>
      <address>
        <city>Little Rock</city>
        <state>Arkansas</state>
        <zip>72211</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Scripps Health</name>
      <address>
        <city>La Jolla</city>
        <state>California</state>
        <zip>92037</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Sequoia Hospital</name>
      <address>
        <city>Redwood City</city>
        <state>California</state>
        <zip>94062</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>South Denver Cardiology Associates, P.C.</name>
      <address>
        <city>Littleton</city>
        <state>Colorado</state>
        <zip>80120</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Washington Hospital Center</name>
      <address>
        <city>Washington</city>
        <state>District of Columbia</state>
        <zip>20010</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Florida Hospital</name>
      <address>
        <city>Orlando</city>
        <state>Florida</state>
        <zip>32803</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Emory University Hospital</name>
      <address>
        <city>Atlanta</city>
        <state>Georgia</state>
        <zip>30322</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Central Baptist Hospital</name>
      <address>
        <city>Lexington</city>
        <state>Kentucky</state>
        <zip>40503</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Mayo Clinic</name>
      <address>
        <city>Rochester</city>
        <state>Minnesota</state>
        <zip>55905</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>New York University Hospital</name>
      <address>
        <city>New York</city>
        <state>New York</state>
        <zip>10016</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Mount Sinai Hospital</name>
      <address>
        <city>New York</city>
        <state>New York</state>
        <zip>10029</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>The Cleveland Clinic Foundation</name>
      <address>
        <city>Cleveland</city>
        <state>Ohio</state>
        <zip>44195</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Medical University of South Carolina</name>
      <address>
        <city>Charleston</city>
        <state>South Carolina</state>
        <zip>29425</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Texas Cardiac Arrhythmia</name>
      <address>
        <city>Austin</city>
        <state>Texas</state>
        <zip>78705</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Ashford Hospital</name>
      <address>
        <city>Adelaide</city>
        <zip>5000</zip>
        <country>Australia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Royal Adelaide Hospital</name>
      <address>
        <city>Adelaide</city>
        <country>Australia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Royal Melbourne Hospital - City Campus</name>
      <address>
        <city>Melbourne</city>
        <zip>3050</zip>
        <country>Australia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Herzzentrum Leipzig GmbH</name>
      <address>
        <city>Leipzig</city>
        <state>Saxony</state>
        <zip>04289</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Herzzentrum Dresden GmbH Universitätsklinik</name>
      <address>
        <city>Dresden</city>
        <zip>01307</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Ospedale San Raffaele</name>
      <address>
        <city>Milan</city>
        <state>Lombardy</state>
        <zip>20132</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Centro Cardiologico Monzino</name>
      <address>
        <city>Milan</city>
        <zip>20138</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Australia</country>
    <country>Germany</country>
    <country>Italy</country>
    <country>United States</country>
  </location_countries>
  <verification_date>January 2020</verification_date>
  <study_first_submitted>November 17, 2017</study_first_submitted>
  <study_first_submitted_qc>November 21, 2017</study_first_submitted_qc>
  <study_first_posted type="Actual">November 28, 2017</study_first_posted>
  <results_first_submitted>August 1, 2019</results_first_submitted>
  <results_first_submitted_qc>August 1, 2019</results_first_submitted_qc>
  <results_first_posted type="Actual">August 20, 2019</results_first_posted>
  <last_update_submitted>January 14, 2020</last_update_submitted>
  <last_update_submitted_qc>January 14, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">January 28, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>paroxysmal atrial fibrillation</keyword>
  <keyword>PAF</keyword>
  <keyword>ablation</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Atrial Fibrillation</mesh_term>
  </condition_browse>
  <provided_document_section>
    <provided_document>
      <document_type>Study Protocol</document_type>
      <document_has_protocol>Yes</document_has_protocol>
      <document_has_icf>No</document_has_icf>
      <document_has_sap>No</document_has_sap>
      <document_date>March 6, 2018</document_date>
      <document_url>https://ClinicalTrials.gov/ProvidedDocs/63/NCT03354663/Prot_000.pdf</document_url>
    </provided_document>
    <provided_document>
      <document_type>Statistical Analysis Plan</document_type>
      <document_has_protocol>No</document_has_protocol>
      <document_has_icf>No</document_has_icf>
      <document_has_sap>Yes</document_has_sap>
      <document_date>March 6, 2018</document_date>
      <document_url>https://ClinicalTrials.gov/ProvidedDocs/63/NCT03354663/SAP_001.pdf</document_url>
    </provided_document>
  </provided_document_section>

  <clinical_results>

    <participant_flow>
      <group_list>
        <group group_id="P1">
          <title>TactiCath SE</title>
          <description>Catheter ablation with the TactiCath SE ablation catheter to achieve pulmonary vein isolation.
TactiCath SE: Ablation to achieve pulmonary vein isolation.</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Enrollment to Catheter Insertion</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="156"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="151"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="5"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Did not meet inc/exc criteria</title>
              <participants_list>
                <participants group_id="P1" count="4"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Adverse Event</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
        <period>
          <title>Completed 30-day Visit</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="151"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="149"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="2"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Withdrawal by Subject</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Missed Visit</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <population>Population includes all subjects with device inserted into vasculature.</population>
      <group_list>
        <group group_id="B1">
          <title>TactiCath SE</title>
          <description>Catheter ablation with the TactiCath SE ablation catheter to achieve pulmonary vein isolation.
TactiCath SE: Ablation to achieve pulmonary vein isolation.</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="151"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>&lt;=18 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Between 18 and 65 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="75"/>
                  </measurement_list>
                </category>
                <category>
                  <title>&gt;=65 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="76"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Median</param>
          <dispersion>Inter-Quartile Range</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="65.0" lower_limit="56.0" upper_limit="71.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Sex: Female, Male</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="60"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="91"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Ethnicity (NIH/OMB)</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Hispanic or Latino</title>
                  <measurement_list>
                    <measurement group_id="B1" value="3"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Not Hispanic or Latino</title>
                  <measurement_list>
                    <measurement group_id="B1" value="125"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Unknown or Not Reported</title>
                  <measurement_list>
                    <measurement group_id="B1" value="23"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Race (NIH/OMB)</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>American Indian or Alaska Native</title>
                  <measurement_list>
                    <measurement group_id="B1" value="1"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Asian</title>
                  <measurement_list>
                    <measurement group_id="B1" value="2"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Native Hawaiian or Other Pacific Islander</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Black or African American</title>
                  <measurement_list>
                    <measurement group_id="B1" value="1"/>
                  </measurement_list>
                </category>
                <category>
                  <title>White</title>
                  <measurement_list>
                    <measurement group_id="B1" value="123"/>
                  </measurement_list>
                </category>
                <category>
                  <title>More than one race</title>
                  <measurement_list>
                    <measurement group_id="B1" value="3"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Unknown or Not Reported</title>
                  <measurement_list>
                    <measurement group_id="B1" value="21"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Region of Enrollment</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>United States</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="101"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Italy</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="12"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Australia</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="22"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Germany</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="21"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>BMI</title>
          <units>kg/m^2</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="28.0" spread="5.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Coronary Artery Disease</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="20"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Heart Failure</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Hypertension</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="80"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Diabetes</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="15"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Stoke/Transient Ischemic Attack</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="14"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Myocardial Infarction</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Obstructive Sleep Apnea</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="20"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Structural Heart Disease</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Known Family History of Cardiovascular Disease</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="81"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Left Ventricular Ejection Fraction</title>
          <units>%</units>
          <param>Median</param>
          <dispersion>Inter-Quartile Range</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="60.7" lower_limit="55.0" upper_limit="65.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Left Atrium Diameter</title>
          <units>centimeters</units>
          <param>Median</param>
          <dispersion>Inter-Quartile Range</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="3.8" lower_limit="3.3" upper_limit="4.3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Pacemaker or Implantable Cardiac Monitor</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="19"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Rate of Serious Adverse Events</title>
        <description>The primary safety endpoint is the rate of device or procedure-related serious adverse events occurring within 7 days of the index procedure. SAEs related solely to arrhythmia recurrence (without coexisting conditions such as thromboembolism, worsening heart failure, etc.) will not be considered primary safety endpoint events. The SAEs that will be included in this endpoint are:
Atrial-esophageal fistula
AV block
Cardiac Perforation/ Tamponade
Death
Diaphragmatic paralysis
Gastroparesis
Hospitalization
Myocardial Infarction
Pericarditis
Pneumothorax
Pulmonary edema
Pulmonary vein stenosis
Stroke
Thromboembolism
Transient ischemic attack
Vascular access complications
Atrial-esophageal fistula, cardiac perforation/tamponade, and pulmonary vein stenosis that occur &gt;7 days post procedure through 30 days will also contribute to the primary endpoint.</description>
        <time_frame>30 days</time_frame>
        <population>All subjects with device inserted into vasculature and either experienced a primary endpoint event or completed 30 days of follow up.</population>
        <group_list>
          <group group_id="O1">
            <title>TactiCath SE - Safety Population</title>
            <description>Catheter ablation with the TactiCath SE ablation catheter to achieve pulmonary vein isolation.
TactiCath SE: Ablation to achieve pulmonary vein isolation.
Includes all subjects with catheter inserted into vasculature.</description>
          </group>
        </group_list>
        <measure>
          <title>Rate of Serious Adverse Events</title>
          <description>The primary safety endpoint is the rate of device or procedure-related serious adverse events occurring within 7 days of the index procedure. SAEs related solely to arrhythmia recurrence (without coexisting conditions such as thromboembolism, worsening heart failure, etc.) will not be considered primary safety endpoint events. The SAEs that will be included in this endpoint are:
Atrial-esophageal fistula
AV block
Cardiac Perforation/ Tamponade
Death
Diaphragmatic paralysis
Gastroparesis
Hospitalization
Myocardial Infarction
Pericarditis
Pneumothorax
Pulmonary edema
Pulmonary vein stenosis
Stroke
Thromboembolism
Transient ischemic attack
Vascular access complications
Atrial-esophageal fistula, cardiac perforation/tamponade, and pulmonary vein stenosis that occur &gt;7 days post procedure through 30 days will also contribute to the primary endpoint.</description>
          <population>All subjects with device inserted into vasculature and either experienced a primary endpoint event or completed 30 days of follow up.</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="149"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
            </group_id_list>
            <groups_desc>The hypothesis is formally expressed as:
H0: P ≥ 16.2% Ha: P &lt; 16.2%, where P is the percentage of subjects with a primary safety endpoint event. The hypothesis will be tested based on a one-sided exact test of binomial proportions at the one-sided 0.05 alpha level.</groups_desc>
            <non_inferiority_type>Other</non_inferiority_type>
            <non_inferiority_desc>Single arm trial</non_inferiority_desc>
            <p_value>&lt;0.0001</p_value>
            <method>Binomial Exact Test</method>
            <param_type>Proportion</param_type>
            <param_value>0.047</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>1-Sided</ci_n_sides>
            <ci_upper_limit>0.0864</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Number of Participants With Procedural Success</title>
        <description>The primary effectiveness endpoint is acute procedural success, where acute procedural success is defined as confirmation of entrance block in all pulmonary veins</description>
        <time_frame>0 days</time_frame>
        <population>Effectiveness Population - all subjects with device inserted into vasculature</population>
        <group_list>
          <group group_id="O1">
            <title>TactiCath SE</title>
            <description>Catheter ablation with the TactiCath SE ablation catheter to achieve pulmonary vein isolation.
TactiCath SE: Ablation to achieve pulmonary vein isolation.</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Participants With Procedural Success</title>
          <description>The primary effectiveness endpoint is acute procedural success, where acute procedural success is defined as confirmation of entrance block in all pulmonary veins</description>
          <population>Effectiveness Population - all subjects with device inserted into vasculature</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="151"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="148"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
            </group_id_list>
            <non_inferiority_type>Other</non_inferiority_type>
            <non_inferiority_desc>The hypothesis is formally expressed as:
H0: P &lt; 90% Ha: P ≥ 90%, where P is the percentage of subjects with acute success. The hypothesis will be tested based on a one-sided exact test of binomial proportions at the one-sided 0.05 alpha level. Rejection of the null hypothesis will indicate study success.</non_inferiority_desc>
            <p_value>0.0001</p_value>
            <method>Binomial Exact Test</method>
            <param_type>Proportion</param_type>
            <param_value>0.98</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>1-Sided</ci_n_sides>
            <ci_lower_limit>0.9495</ci_lower_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Other Pre-specified</type>
        <title>Average Power Delivered</title>
        <description>This outcome is the average power delivered for a case.</description>
        <time_frame>During Procedure</time_frame>
        <population>The population includes only subjects with at least some radiofrequency energy delivered.</population>
        <group_list>
          <group group_id="O1">
            <title>RF Population</title>
            <description>Group of subjects with at least some RF energy delivered</description>
          </group>
        </group_list>
        <measure>
          <title>Average Power Delivered</title>
          <description>This outcome is the average power delivered for a case.</description>
          <population>The population includes only subjects with at least some radiofrequency energy delivered.</population>
          <units>Watts</units>
          <param>Median</param>
          <dispersion>Inter-Quartile Range</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="150"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="29.0" lower_limit="26.0" upper_limit="32.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Other Pre-specified</type>
        <title>Index Cases Achieving ≥ 90% Lesions With ≥ 10 Contact Force</title>
        <description>Proportion of index cases achieving ≥ 90% lesions with ≥10g contact force</description>
        <time_frame>0 days</time_frame>
        <population>Population includes all subjects with at least some radiofrequency energy delivered.</population>
        <group_list>
          <group group_id="O1">
            <title>RF Population</title>
            <description>Group of subjects with at least some RF energy delivered</description>
          </group>
        </group_list>
        <measure>
          <title>Index Cases Achieving ≥ 90% Lesions With ≥ 10 Contact Force</title>
          <description>Proportion of index cases achieving ≥ 90% lesions with ≥10g contact force</description>
          <population>Population includes all subjects with at least some radiofrequency energy delivered.</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="149"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Other Pre-specified</type>
        <title>Number of Participants Experiencing Serious Adverse Events Within 30 Days</title>
        <description>Serious adverse events and adverse events related to the procedure and/or ablation catheter through 30 days post index ablation. This excludes the events identified in the primary safety endpoint.</description>
        <time_frame>30 days</time_frame>
        <population>Population includes all subjects with ablation catheter inserted.</population>
        <group_list>
          <group group_id="O1">
            <title>TactiCath SE</title>
            <description>Catheter ablation with the TactiCath SE ablation catheter to achieve pulmonary vein isolation.
TactiCath SE: Ablation to achieve pulmonary vein isolation.</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Participants Experiencing Serious Adverse Events Within 30 Days</title>
          <description>Serious adverse events and adverse events related to the procedure and/or ablation catheter through 30 days post index ablation. This excludes the events identified in the primary safety endpoint.</description>
          <population>Population includes all subjects with ablation catheter inserted.</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="151"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Servious AE Related to Device or Procedure</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Non-Serious AE Related to Device or Procedure</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="23"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Other Pre-specified</type>
        <title>Number of Participants Experiencing a Serious Adverse Event Within 1 Year</title>
        <description>Serious adverse events and adverse events related to the procedure and/or ablation catheter through 1 year post index ablation</description>
        <time_frame>1 year</time_frame>
        <posting_date>06/2020</posting_date>
      </outcome>
      <outcome>
        <type>Other Pre-specified</type>
        <title>One-year Freedom From AF</title>
        <description>One-year freedom from AF, defined as freedom from symptomatic AF, atrial flutter (AFL), and atrial tachycardia (AT) lasting longer than 30 seconds through 9 months of follow-up after a 3-month blanking period.</description>
        <time_frame>1 year</time_frame>
        <posting_date>06/2020</posting_date>
      </outcome>
      <outcome>
        <type>Other Pre-specified</type>
        <title>One-year Drug-free Success From AF</title>
        <description>One-year drug-free success defined as freedom from any AF/AFL/AT lasting at least 30 seconds or any Class I or III AAD after removal from antiarrhythmic drug therapy as assessed from the end of the 3-month blanking period to 12 months following the ablation procedure.</description>
        <time_frame>1 year</time_frame>
        <posting_date>06/2020</posting_date>
      </outcome>
      <outcome>
        <type>Other Pre-specified</type>
        <title>Changes in EQ-5D-5L Scores</title>
        <description>Changes in EQ-5D-5L scores from baseline to follow up at 3, 6, and 12 months</description>
        <time_frame>1 year</time_frame>
        <posting_date>06/2020</posting_date>
      </outcome>
      <outcome>
        <type>Other Pre-specified</type>
        <title>Changes in AFEQT Scores</title>
        <description>Changes in AFEQT scores from baseline to follow up at 3, 6, and 12 months</description>
        <time_frame>1 year</time_frame>
        <posting_date>06/2020</posting_date>
      </outcome>
      <outcome>
        <type>Other Pre-specified</type>
        <title>Health Care Utilization</title>
        <description>Cardiovascular-related health care utilization through 12 months post index ablation</description>
        <time_frame>1 year</time_frame>
        <posting_date>06/2020</posting_date>
      </outcome>
      <outcome>
        <type>Other Pre-specified</type>
        <title>Force Time Integral (FTI) and Lesion Index (LSI)</title>
        <description>FTI and LSI will be derived from the available EnSite Precision data. Descriptive statistics will be generated for both variables.</description>
        <time_frame>0 days</time_frame>
        <posting_date>06/2020</posting_date>
      </outcome>
      <outcome>
        <type>Other Pre-specified</type>
        <title>Average Catheter Temperature</title>
        <description>This outcome is the average temperature (by lesion) for a case.</description>
        <time_frame>0 days</time_frame>
        <population>The population includes only subjects with at least some radiofrequency energy delivered.</population>
        <group_list>
          <group group_id="O1">
            <title>RF Population</title>
            <description>Group of subjects with at least some RF energy delivered</description>
          </group>
        </group_list>
        <measure>
          <title>Average Catheter Temperature</title>
          <description>This outcome is the average temperature (by lesion) for a case.</description>
          <population>The population includes only subjects with at least some radiofrequency energy delivered.</population>
          <units>degrees celsius</units>
          <param>Median</param>
          <dispersion>Inter-Quartile Range</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="149"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="33.4" lower_limit="32.5" upper_limit="34.6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Other Pre-specified</type>
        <title>Number of Participants With Recommended Irrigation Flow Rate Used During Procedure</title>
        <description>This outcome is whether or not the recommended irrigation flow rate was used for a case.</description>
        <time_frame>0 days</time_frame>
        <population>The population includes only subjects with at least some radiofrequency energy delivered.</population>
        <group_list>
          <group group_id="O1">
            <title>RF Population</title>
            <description>Group of subjects with at least some RF energy delivered</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Participants With Recommended Irrigation Flow Rate Used During Procedure</title>
          <description>This outcome is whether or not the recommended irrigation flow rate was used for a case.</description>
          <population>The population includes only subjects with at least some radiofrequency energy delivered.</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="150"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="140"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Other Pre-specified</type>
        <title>Contact Force During Procedure</title>
        <description>This outcome is the average contact force for a case.</description>
        <time_frame>0 days</time_frame>
        <population>The population includes only subjects with at least some radiofrequency energy delivered.</population>
        <group_list>
          <group group_id="O1">
            <title>RF Population</title>
            <description>Group of subjects with at least some RF energy delivered</description>
          </group>
        </group_list>
        <measure>
          <title>Contact Force During Procedure</title>
          <description>This outcome is the average contact force for a case.</description>
          <population>The population includes only subjects with at least some radiofrequency energy delivered.</population>
          <units>grams</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="149"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="12.1" spread="4.7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Other Pre-specified</type>
        <title>Total Procedure Time</title>
        <description>This outcome is the total procedure time for a case.</description>
        <time_frame>0 days</time_frame>
        <population>The population includes only subjects with at least some radiofrequency energy delivered.</population>
        <group_list>
          <group group_id="O1">
            <title>RF Population</title>
            <description>Group of subjects with at least some RF energy delivered</description>
          </group>
        </group_list>
        <measure>
          <title>Total Procedure Time</title>
          <description>This outcome is the total procedure time for a case.</description>
          <population>The population includes only subjects with at least some radiofrequency energy delivered.</population>
          <units>minutes</units>
          <param>Median</param>
          <dispersion>Inter-Quartile Range</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="150"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="159.5" lower_limit="123.0" upper_limit="206.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Other Pre-specified</type>
        <title>Ablation Time - First to Last Ablation</title>
        <description>This outcome is the total ablation time for a case. This is the time from first to last ablation.</description>
        <time_frame>0 Days</time_frame>
        <population>The population includes only subjects with at least some radiofrequency energy delivered.</population>
        <group_list>
          <group group_id="O1">
            <title>RF Population</title>
            <description>Group of subjects with at least some RF energy delivered</description>
          </group>
        </group_list>
        <measure>
          <title>Ablation Time - First to Last Ablation</title>
          <description>This outcome is the total ablation time for a case. This is the time from first to last ablation.</description>
          <population>The population includes only subjects with at least some radiofrequency energy delivered.</population>
          <units>minutes</units>
          <param>Median</param>
          <dispersion>Inter-Quartile Range</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="150"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="84.0" lower_limit="56.0" upper_limit="127.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Other Pre-specified</type>
        <title>Fluoroscopy Time</title>
        <description>This outcome is the total fluoroscopy time for a case.</description>
        <time_frame>0 days</time_frame>
        <population>The population includes only subjects with at least some radiofrequency energy delivered.</population>
        <group_list>
          <group group_id="O1">
            <title>RF Population</title>
            <description>Group of subjects with at least some RF energy delivered</description>
          </group>
        </group_list>
        <measure>
          <title>Fluoroscopy Time</title>
          <description>This outcome is the total fluoroscopy time for a case.</description>
          <population>The population includes only subjects with at least some radiofrequency energy delivered.</population>
          <units>minutes</units>
          <param>Median</param>
          <dispersion>Inter-Quartile Range</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="150"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="9.0" lower_limit="5.0" upper_limit="16.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Other Pre-specified</type>
        <title>Radiofrequency (RF) Application Time</title>
        <description>This outcome is the total RF application time for a case.</description>
        <time_frame>0 days</time_frame>
        <population>The population includes only subjects with at least some radiofrequency energy delivered.</population>
        <group_list>
          <group group_id="O1">
            <title>RF Population</title>
            <description>Group of subjects with at least some RF energy delivered</description>
          </group>
        </group_list>
        <measure>
          <title>Radiofrequency (RF) Application Time</title>
          <description>This outcome is the total RF application time for a case.</description>
          <population>The population includes only subjects with at least some radiofrequency energy delivered.</population>
          <units>minutes</units>
          <param>Median</param>
          <dispersion>Inter-Quartile Range</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="149"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="35.7" lower_limit="28.9" upper_limit="51.9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Other Pre-specified</type>
        <title>Number of Participants Using AutoMark</title>
        <description>This outcome is the number of cases using AutoMark.</description>
        <time_frame>0 days</time_frame>
        <population>The population includes only subjects with at least some radiofrequency energy delivered.</population>
        <group_list>
          <group group_id="O1">
            <title>RF Population</title>
            <description>Group of subjects with at least some RF energy delivered</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Participants Using AutoMark</title>
          <description>This outcome is the number of cases using AutoMark.</description>
          <population>The population includes only subjects with at least some radiofrequency energy delivered.</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="150"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="149"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>30 days</time_frame>
      <desc>Adverse events include events that are not necessarily related to the device or procedure.</desc>
      <group_list>
        <group group_id="E1">
          <title>TactiCath SE</title>
          <description>Catheter ablation with the TactiCath SE ablation catheter to achieve pulmonary vein isolation.
TactiCath SE: Ablation to achieve pulmonary vein isolation.</description>
        </group>
      </group_list>
      <serious_events>
        <default_assessment>Non-systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, all-cause mortality</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="156"/>
              </event>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="21" subjects_at_risk="156"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Blood and lymphatic system disorders</title>
            <event_list>
              <event>
                <sub_title>Vascular Bleeding/Local Hematomas/Ecchymosis</sub_title>
                <assessment>Systematic Assessment</assessment>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="156"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Cardiac disorders</title>
            <event_list>
              <event>
                <sub_title>Arrhythmias</sub_title>
                <assessment>Systematic Assessment</assessment>
                <counts group_id="E1" events="8" subjects_affected="7" subjects_at_risk="156"/>
              </event>
              <event>
                <sub_title>Cardiac Perforation/Tamponade</sub_title>
                <assessment>Systematic Assessment</assessment>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="156"/>
              </event>
              <event>
                <sub_title>Pericardial Effusion</sub_title>
                <assessment>Systematic Assessment</assessment>
                <counts group_id="E1" events="3" subjects_affected="3" subjects_at_risk="156"/>
              </event>
              <event>
                <sub_title>Pericarditis</sub_title>
                <assessment>Systematic Assessment</assessment>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="156"/>
              </event>
              <event>
                <sub_title>Ventricular Tachyarrhythmia</sub_title>
                <assessment>Systematic Assessment</assessment>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="156"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Atrial-Esophageal Fistula</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="156"/>
              </event>
              <event>
                <sub_title>Infections</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="156"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>Syncope/Dizziness</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="156"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Hepatobiliary disorders</title>
            <event_list>
              <event>
                <sub_title>Cholecystitis</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="156"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>Infections</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="156"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Neoplasms benign, malignant and unspecified (incl cysts and polyps)</title>
            <event_list>
              <event>
                <sub_title>Gastroparesis</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="156"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>Cerebrovascular Accident/ Stroke</sub_title>
                <assessment>Systematic Assessment</assessment>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="156"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Renal and urinary disorders</title>
            <event_list>
              <event>
                <sub_title>Urinary Retention</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="156"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Vascular disorders</title>
            <event_list>
              <event>
                <sub_title>Hypertension</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="156"/>
              </event>
              <event>
                <sub_title>Thromboembolism</sub_title>
                <assessment>Systematic Assessment</assessment>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="156"/>
              </event>
              <event>
                <sub_title>Vascular Damage</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="156"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>0</frequency_threshold>
        <default_assessment>Non-systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="25" subjects_at_risk="156"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Cardiac disorders</title>
            <event_list>
              <event>
                <sub_title>Chest Pain/Discomfort</sub_title>
                <counts group_id="E1" events="5" subjects_affected="5" subjects_at_risk="156"/>
              </event>
              <event>
                <sub_title>Pericardial Effusion</sub_title>
                <assessment>Systematic Assessment</assessment>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="156"/>
              </event>
              <event>
                <sub_title>Pericarditis</sub_title>
                <assessment>Systematic Assessment</assessment>
                <counts group_id="E1" events="6" subjects_affected="6" subjects_at_risk="156"/>
              </event>
              <event>
                <sub_title>Syncope/Dizziness</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="156"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Epigastric Fullness</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="156"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>Low Grade Temp</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="156"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>Infections</sub_title>
                <counts group_id="E1" events="3" subjects_affected="3" subjects_at_risk="156"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Musculoskeletal and connective tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Wrist Pain With Swelling And Bruising</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="156"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Renal and urinary disorders</title>
            <event_list>
              <event>
                <sub_title>Infections</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="156"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Skin and subcutaneous tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Allergic Reaction</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="156"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Vascular disorders</title>
            <event_list>
              <event>
                <sub_title>Hypotension</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="156"/>
              </event>
              <event>
                <sub_title>Vascular Access Complication</sub_title>
                <assessment>Systematic Assessment</assessment>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="156"/>
              </event>
              <event>
                <sub_title>Vascular Bleeding/Local Hematomas/Ecchymosis</sub_title>
                <assessment>Systematic Assessment</assessment>
                <counts group_id="E1" events="3" subjects_affected="3" subjects_at_risk="156"/>
              </event>
              <event>
                <sub_title>Volume Overload</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="156"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>The only disclosure restriction on the PI is that the sponsor can review results communications prior to public release and can embargo communications regarding trial results for a period that is less than or equal to 60 days. The sponsor cannot require changes to the communication and cannot extend the embargo.</restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Steven Madej</name_or_title>
      <organization>Abbott</organization>
      <phone>651-756-2230</phone>
      <email>steven.madej@abbott.com</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

